AHA: CANTOS Substudy Supports Major Role Of Inflammation - MedPage Today

KFGO

AHA: CANTOS Substudy Supports Major Role Of Inflammation MedPage Today ANAHEIM -- An important CANTOS trial substudy bolsters evidence that inflammation plays an independent role in cardiovascular disease (CVD) and may point toward a new targeted approach to treatment of CVD and perhaps even more profoundly impact ... Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participantsPR Newswire (press release) Prepping a case for canakinumab, Novartis tries to stake out a high-value segment of huge cardio marketEndpoints News all 5 news articles »

from Health - Google News http://ift.tt/2yYKgaN